Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Pfs230D1M-EPA and Pfs25M-EPA Malaria Transmission-Blocking Vaccines
NCT02334462Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2015
- Primary completion
- Mar 2016
- Modality
- Nanoparticles, Split/Subunit Vaccines, Peptide-Protein Conjugates
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of Pfs25M-EPA + Alhydrogel and pfs230d1m-epa + alhydrogel in malaria (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Incidence of local and systemic adverse events and serious adverse events at Day 730. Started Jan 2015; status: completed.
02
Drugs
Pfs25M-EPA + Alhydrogelpfs230d1m-epa + alhydrogel
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02334462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334462.